ARGOS THERAPEUTICS INC's ticker is ARGSXXXX and the CUSIP is 040221103. A total of 21 filers reported holding ARGOS THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $600,000 | +1566.7% | 200,000 | 0.0% | 0.01% | – |
| Q3 2017 | $36,000 | -50.7% | 200,000 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $73,000 | -18.9% | 200,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $90,000 | -90.8% | 200,000 | 0.0% | 0.00% | -87.5% |
| Q4 2016 | $980,000 | -36.7% | 200,000 | -35.8% | 0.01% | -42.9% |
| Q3 2016 | $1,548,000 | +231.5% | 311,424 | +54.1% | 0.01% | +180.0% |
| Q4 2015 | $467,000 | -32.7% | 202,144 | +40.4% | 0.01% | -37.5% |
| Q3 2015 | $694,000 | -61.8% | 144,025 | -45.7% | 0.01% | -27.3% |
| Q2 2015 | $1,816,000 | +29.8% | 265,168 | +68.9% | 0.01% | -42.1% |
| Q1 2015 | $1,399,000 | +38.9% | 157,035 | +55.9% | 0.02% | +11.8% |
| Q4 2014 | $1,007,000 | +26.0% | 100,701 | +26.8% | 0.02% | +6.2% |
| Q3 2014 | $799,000 | -26.4% | 79,430 | -41.3% | 0.02% | -33.3% |
| Q2 2014 | $1,086,000 | -5.2% | 135,237 | +18.0% | 0.02% | -22.6% |
| Q1 2014 | $1,146,000 | – | 114,586 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 13,242,279 | $64,887,000 | 55.88% |
| Pharmstandard International S.A. | 5,120,604 | $27,390,000 | 23.59% |
| SANDERS MORRIS HARRIS LLC | 292,512 | $1,433,000 | 0.66% |
| WALL STREET ASSOCIATES | 82,850 | $406,000 | 0.27% |
| WASATCH ADVISORS LP | 3,254,211 | $15,946,000 | 0.24% |
| ALTRINSIC GLOBAL ADVISORS LLC | 172,505 | $845,000 | 0.03% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 121,524 | $595,000 | 0.01% |
| Alyeska Investment Group, L.P. | 200,000 | $980,000 | 0.01% |
| Acrospire Investment Management LLC | 1,800 | $9,000 | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,024,428 | $5,020,000 | 0.00% |